Cell Source, Inc. operates as a cell therapy company focused on immunotherapy. Its Veto Cell technology is a next generation immunotherapy technology that enables the selective attenuation of the immune system. The company's Veto Cell platform roadmap consists of two main programs: VETO CAR-T (with and without HSCT) and Veto Cell Organ Transplantation. The company was founded on June 6, 2012 and is headquartered in New York, NY.